ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

CIS-アトバコン

3-(4-(4-Chlorophenyl)cyclohexyl)-4-hydroxynaphthalene-1,2-dione

HCID 74989
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
137732-39-9
標準SMILES
O=C1C(=O)c2ccccc2C(O)=C1C1CCC(c2ccc(Cl)cc2)CC1
InChIKey
BSJMWHQBCZFXBR-UHFFFAOYSA-N
分子式
C22H19ClO3
平均分子量
366.8 g/mol
単同位体質量
366.1022722

概要

Atovaquone is a naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. It has a role as an antifungal agent, an antimalarial, an EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor, an EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor and an EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor. It is a hydroxy-1,4-naphthoquinone and a member of monochlorobenzenes.

名称と識別子

優先名称
3-(4-(4-Chlorophenyl)cyclohexyl)-4-hydroxynaphthalene-1,2-dione
IUPAC
3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dione
現地名
CIS-アトバコン
英語名
cis-Atovaquone
分子式
C22H19ClO3
分子量
366.84

名称と別名

3-[4-(4-chlorophenyl)cyclohexyl]-4-hydroxynaphthalene-1,2-dioneDTXSID209166943-(4-(4-chlorophenyl)cyclohexyl)-4-hydroxynaphthalene-1,2-dioneRefChem:1066764DTXCID20888847630-425-2ATOVAQUONE95233-18-4MepronWellvonecis-AtovaquoneAcuvel
名称をさらに表示
CIS-アトバコンcis-Atovaquone-d4Atovaquone EP Imp BAtovaquone Impurity 17Atovaquone EP Impurity B (RC A)Atovaquone Impurity 2(Atovaquone EP Impurity B)Atovaquone EP Impurity B (Atovaquone Related Compound A)Atovaquone EP Impurity B (Atovaquone USP Related Compound A)
137732-39-9Atavaquone94015-53-9566C80Mepron (antipneumocystic)CIS-ATOVAQUONE (RACEMIC)Atovaquone EP Impurity BBW 566C

データベース識別子

CAS

物性

構造計算による物性補完中

XLogP
5.2
極性表面積
54.4 Ų
水素結合供与体数
1
水素結合受容体数
3
回転可能結合数
2
重原子数
26
形式電荷
0
複雑度
595

実験および物理化学的性質

Drugs · 3 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

LogP5.07
SolubilityPractically insoluble
Collision Cross Section174.53 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
40 °C · >40°C (dec.)
沸点
535 · 535.0±50.0 °C(Predicted)
比重(密度)
1.349 · 1.349±0.06 g/cm3(Predicted)
貯蔵温度
Room Temperature, under inert atmosphere
溶解性
クロロホルム(微量)、ジクロロメタン(微量、アセトニトリル)
酸解離定数(Pka)
5.01 · 5.01±0.10(Predicted)
外見
個体
色
淡黄色~淡黄色
主な用途
医薬品(低分子化合物)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Hazard Classes and CategoriesSkin Irrit. 2 (100%)

安全データ

wgk
3
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC CodeP01AX06
Protein BindingAtovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 µg/mL.
Pharmacodynamics · 1 件

Atovaquone is a highly lipophilic drug that closely resembles the structure [ubiquinone]. Its inhibitory effect being comparable to ubiquinone, atovaquone can act by selectively affecting mitochondrial electron transport and parallel processes such as ATP and pyrimidine biosynthesis in atovaquone-responsive parasites. Cytochrome bc1 complex (complex III) seems to serve as a highly discriminating molecular target for atovaquone in Plasmodia. There is no significant risk for myelosuppression associated with atovaquone, making this drug a beneficial therapeutic agent for recipients of bone marrow transplantation.

Mechanism of Action · 1 件

The mechanism of action against <i>Pneumocystis carinii</i> has not been fully elucidated. In Plasmodium species, the site of action appears to be the cytochrome bc1 complex (Complex III). Several metabolic enzymes are linked to the mitochondrial electron transport chain via ubiquinone. Inhibition of electron transport by atovaquone will result in indirect inhibition of these enzymes. The ultimate metabolic effects of such blockade may include inhibition of nucleic acid and ATP synthesis. Atovaquone also has been shown to have good <i>in vitro</i> activity against <i>Toxoplasma gondii</i>.

Biological Half-Life2.2 to 3.2 days
Metabolism/MetabolitesSome evidence suggests limited metabolism (although no metabolites have been identified).
Absorption, Distribution and Excretion · 4 件

The bioavailability of atovaquone is low and variable and is highly dependent on formulation and diet. Bioavailability of the suspension increases two-fold when administered with meals. When administered with food, bioavailability is approximately 47%. Without food, the bioavailability is 23%.

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
137732-39-9、94015-53-9、95233-18-4
PubChem CID
74989
DTXSID
DTXSID20916694
ChEMBL
CHEMBL471792、CHEMBL519462
ChEBI
CHEBI:575568
UNII
F1W7QUV0KI、Y883P1Z2LT
EC Number
689-795-9
Nikkaji
J1.549.967B、J389.528I

The half-life of atovaquone is long due to presumed enterohepatic cycling and eventual fecal elimination. There was little or no excretion of atovaquone in the urine (less than 0.6%).

0.60 ± 0.17 L/kg

10.4 +/- 5.5 ml/min [HIV-infected patients receiving IV administration]

応用分野

使用cis-Atovaquone is the cis-isomer of Atovaquone (A793500), a hydroxynaphthoquinone derivative that inhibits mitochondrial electron transport.